Benny Yang
Chief Scientific Officer Biocytogen Boston Corp
Seminars
Tuesday 13th October 2026
RenSuper Biologics: Empowering Next-Generation Dual Payload ADCs With AI Driven Precision & Scalability
12:30 pm
- Leveraging RenLite common light chain to eliminate mismatching, ensuring high homogeneity and “antibody like” stability for complex dual payload formats
- Combining two distinct, complementary MoAs on a single molecule to tackle tumor heterogeneity and bypass resistance
- The RenSuper Workstation AI Platform scans 200+ TAA targets and hundreds of thousands of ready-to go antibodies to match the ideal lead with optimal internalization in record time
